Company intelligence / Profile preview

Cardiapex

Sydney, New South Wales, Australiapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

Cardiex has developed and commercialized FDA-cleared medical devices and digital solutions for noninvasive measurement of central aortic pressures and vascular biomarkers. Their SphygmoCor® platform is widely used in clinical practice to assess cardiovascular risk, guide treatment decisions, and monitor the efficacy of interventions. The company’s latest product, CONNEQT Pulse, is positioned as the first connected vascular biometric monitor targeting both clinical and home use.

Therapeutic areas: NeurologyMetabolic DisordersCardiovascularNephrology
Modalities: DeviceDigital biomarkerDiagnostic technology
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Cardiapex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiapex.

Explore the full profile